Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
03/10/15

VIBATIV(R) (Telavancin) Commercial Team Expanded in Target Geographies, Registry Study Initiated and Telavancin Phase 3 Bacteremia Study Underway; Pipeline Progressing; TD-4208 Advancing to Phase 3 Registrational Program, and Partnered With Mylan in Broad Development and Commercialization Collaboration

03/04/15
GEORGE TOWN, CAYMAN ISLANDS -- ( Marketwired ) -- 03/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (the "Company") announced today that stock options to purchase an aggregate of 10,500 of the Company's ordinary shares were granted to three new non-executive officer employees on March 2, 2015 .
03/03/15
GEORGE TOWN, GRAND CAYMAN -- ( Marketwired ) -- 03/03/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2014 after market close on Tuesday, March 10, 2015 .
02/24/15

Trial Designed to Support Regulatory Filing; Potential to Expand Label for VIBATIV(R) (telavancin) to Third Difficult-to-Treat, Gram-Positive Infection Type

02/10/15

First Patient Enrolled in Telavancin Observational Use Registry (TOUR); Large-Scale Study to Create Knowledge Base to Guide Optimal Clinical Use and Future Development of VIBATIV(R)

02/04/15
GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Renee Gala, Chief Financial Officer, Brett Haumann , Senior Vice President, Clinical Development and Operations, and Frank Pasqualone , Senior Vice President, Operations will
02/03/15
GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/03/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (the "Company") announced today that stock options to purchase an aggregate of 34,375 of the Company's ordinary shares were granted to 14 new non-executive officer employees on February 2, 2015 .
02/02/15

Phase 3 Registrational Studies of TD-4208 Are Anticipated to Begin in 2015

01/05/15
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/05/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , that stock options to purchase an aggregate of 114,500 of the Company's
12/09/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/09/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc. , a reminder that the Company will host an Investor and Analyst Day for